Twelve months later, Miller is healthy and preparing to host her family's holiday gathering. A regimen of biological drugs ...

End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA - - Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 - - Over ...

Health, NEWS - Catharina Hospital and Eindhoven University of Technology (TU/e) have received over €1.3 million for research ...

Targeted radioactive implants combined with chemotherapy are transforming inoperable pancreatic cancer into surgical ...

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit Looks Back at Pancreatic Cancer in 2025: A Year of Progress, ...

A research group at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has identified a candidate ...

Researchers at the University of Houston are pushing the boundaries of biomedical innovation with a discovery that could ...

UT Health San Antonio Multispecialty and Research Hospital became the first in South Texas to use an emerging and less-invasive treatment called radiofrequency ablation on a comorbid patient with a ...

Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speedApplication ...

Phase 1a/1b study in 97 patients demonstrates mitochondrial metabolic reprogramming induced by BPM31510-IV and supports advancement in multiple ...